基于多维EEG特征的神经生理机制和SSRI治疗应对抑郁症的预测建模,基于多维EEG特征
Gang Li1, Boyi Huang2, Yuling Wang3
1College of Mathematical Medicine, Zhejiang Normal University, Jinhua, 321004, China.
Journal of affective disorders
|October 18, 2025
概括
这项研究开发了一种基于脑电图 (EEG) 的机器学习模型,以预测选择性血清素再吸收抑制剂 (SSRI) 在抑郁症中的疗效. 该模型实现了高精度,识别了Beta2振荡和远程连接作为治疗反应的潜在生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 计算精神病学是一种计算精神病学.
- 生物标志物发现发现
背景情况:
- 抑郁症治疗的反应是高度可变的.
- 预测选择性血清素再吸收抑制剂 (SSRI) 的疗效仍然是一个挑战.
- 神经生理学标记可以改善治疗选择.
研究的目的:
- 开发基于脑电图 (EEG) 的机器学习模型,用于预测SSRI疗效.
- 整合多维EEG特征,以提高预测准确度.
- 阐明SSRI反应背后的神经生理机制.
主要方法:
- 从27名抑郁症患者 (数据集I) 和5名验证患者 (数据集II) 收集的静止状态EEG数据.
- 提取的EEG特征包括相对功率 (RP),模糊 (FE) 和相位滞后指数 (PLI).
- 使用了具有递归特征消除 (RFE) 和分类器 (XGBoost,SVM,RF,LightGBM) 的机器学习框架.
主要成果:
- 在使用12秒EEG窗口预测SSRI疗效时,SVM-RFE模型实现了96.83%的准确性.
- 独立验证证实了该模型的通用性.
- 受访者表现出更高的Beta2功率和更高的远程功能连接,特别是在前线网络中.
结论:
- 开发的框架准确地预测SSRI疗效,并很好地对独立数据进行概括.
- 贝塔2振荡和远程连接是SSRI治疗反应的潜在可靠生物标志物.
- 这些发现提供了对抗抑郁药疗效的神经生理学基础的见解.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
806
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
806
Depressive Disorders: Etiology
437
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
437
Electroconvulsive Therapy
864
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
864


